Sodium Tauroursodeoxycholate (TUDC)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Sodium tauroursodeoxycholate (TUDC) 对胆汁淤积具有治疗效果[1,2]。在人红细胞中，它抑制胆汁盐诱导的2’,7’-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF)外流，IC50值为560 μM [3]。
胆汁淤积是胆汁生成障碍所引起的病症，胆汁生成具有重要作用[4]。
cVA-of-CLF意味着 cholyllysylfluorescein的小管空泡累积[1]。CLF的cVA是总胆汁分泌参数[5]。用17βEG培养会剂量依赖性的减少细胞的cVA-of-CLF。50 μM浓度的17βEG使cVA-of-CLF下降40％。同时用TUDC和17βEG培养将cVA 的下降改善24％。同时用SAMe和17βEG培养将cVA 的下降改善18％。与TUDC相比，同时用TUDC、17βEG和SAMe培养将cVA 的下降改善28％。但是TUDC和SAMe的共同效果并不比任何保护剂的单独效果显著[1]。
在大鼠中，腹腔给药500 μg/kg的毒伞素7天，引起肝内胆汁淤积。在这些给药大鼠中，胆汁流量减少，谷丙转氨酶、亮氨酸氨肽酶、血清碱性磷酸酶的活性以及胆汁酸、磷脂和胆固醇的浓度升高。但是，tauroursodeoxycholate显著抑制这些效应。在这些大鼠中，tauroursodeoxycholate显著地改善了胆汁胆固醇和磷脂的排泄率[2]。
参考文献：
[1]. Milkiewicz P, Roma MG, Cardenas R, et al. Effect of tauroursodeoxycholate and S-adenosyl-l-methionine on 17β-estradiol glucuronide-induced cholestasis. Journal of hepatology, 2001, 34(2): 184-191.
[2]. Ishizaki K, Kinbara S, Hirabayashi N, et al. Effect of sodium tauroursodeoxycholate on phalloidin-induced cholestasis in rats. European journal of pharmacology, 2001, 421(1): 55-60.
[3]. Mrowczynska L, Bobrowska-Hgerstrand M, Wrobel A, et al. Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts. Anticancer research, 2005, 25(5): 3173-3178.
[4]. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. New England Journal of Medicine, 1998, 339(17): 1217-1227.
[5]. Milkiewicz P, Roma MG, Elias E, et al. Hepatoprotection with tauroursodeoxycholate and β muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways. Gut, 2002, 51(1): 113-119.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 521.69 |
| Cas No. | 35807-85-3 |
| Formula | C26H44NNaO6S |
| Solubility | ≥26.1 mg/mL in DMSO; ≥2.61 mg/mL in EtOH with gentle warming and ultrasonic; ≥8.42 mg/mL in H2O |
| Chemical Name | sodium (R,Z)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-(2-sulfoethyl)pentanimidate |
| SDF | Download SDF |
| Canonical SMILES | C[C@]([C@@]1([H])CC[C@@]2([H])[C@@]([C@](O)([H])C[C@]3([H])C[C@@](O)([H])CC[C@@]34C)([H])[C@]4([H])CC[C@]12C)([H])CC/C([O-])=N/CCS(O)(=O)=O.[Na+] |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
质量控制和MSDS
- 批次:
化学结构
